aTyr Pharma (ATYR) AI Stock Analysis

• Market Cap: $443.24M
• Dividend Yield: N/A
• Average Volume (3M): 2.19M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: -100.00%
• EPS Growth: 10.73%
• Country: US
• Employees: 56
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.17
• Shares Outstanding: 89,004,430
• 10 Day Avg. Volume: 2,398,572
• 30 Day Avg. Volume: 2,186,933
• PEG Ratio: 0.11
• Price to Book (P/B): 0.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.13
• Enterprise Value/Market Cap: 0.11
• Enterprise Value/Revenue: 47.94
• Enterprise Value/Gross Profit: -132.43
• Enterprise Value/Ebitda: -0.20
• 1Y Price Target: $23.60
• Price Target Upside: 344.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 51 Neutral
• Price Target: $5.50 ▲(3.58%Upside)

aTyr Pharma's overall score is primarily impacted by its financial challenges, with ongoing losses and cash flow issues posing significant risks. Despite this, the stock demonstrates technical strength with strong upward momentum. Valuation concerns due to a negative P/E ratio further weigh on the score.

Positive Factors

Drug Potential

Increasing confidence in efzofitimod's potential for significant steroid reduction and quality of life improvement in pulmonary sarcoidosis.

Market Interest

Investors are eagerly anticipating the Phase 3 trial results for efzofitimod in pulmonary sarcoidosis, indicating strong interest in the drug's potential.

Safety Profile

Efzofitimod was well-tolerated, with no treatment-related adverse events reported, highlighting its safety profile.

Negative Factors

Clinical Trial Data

Minimal clinically important difference for SSc-ILD is an improvement of 4-6 points at 12 months, contrasting with the shorter-term data presented.

Data Interpretation

The company did not provide specifics regarding the dose used in the patients, leading to some uncertainty in data interpretation.

aTyr Pharma Business Overview & Revenue Model

Company Description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

How the Company Makes Money

aTyr Pharma makes money primarily through the development and commercialization of its proprietary therapeutic candidates. The company's revenue model is centered around advancing its pipeline of drug candidates through clinical trials and eventually bringing successful treatments to the market. Revenue streams may include milestone payments, licensing agreements, and collaborations with larger pharmaceutical companies. These partnerships can provide significant financial support and resources, allowing aTyr Pharma to further its research and development efforts. Additionally, the company may generate income through grants and funding from governmental and non-governmental organizations interested in supporting innovative medical research.

aTyr Pharma Financial Statement Overview

Summary

aTyr Pharma is facing major financial challenges with negative profitability, declining revenue, and negative cash flows. However, it maintains a strong equity position and manageable debt level.

Income Statement

aTyr Pharma's income statement shows significant challenges with sustained negative profitability. The gross profit margin was 100% in 2024 due to minimal revenue, but the company has a consistent negative net profit margin due to high expenses outweighing revenue, with a net income of -$64 million in 2024. Revenue growth was negative at -33.43% from 2023 to 2024, indicating a decline in sales. The EBIT and EBITDA margins are both negative, reflecting ongoing operational losses.

Balance Sheet

The balance sheet shows a moderate financial position for aTyr Pharma. The debt-to-equity ratio is relatively low at 0.19, suggesting manageable leverage. However, the return on equity (ROE) is negative due to substantial net losses impacting shareholder value. The equity ratio stands at 72.33%, indicating a strong equity position relative to total assets.

Cash Flow

Cash flow analysis for aTyr Pharma reveals ongoing operational cash deficits, with an operating cash flow of -$69 million in 2024. The free cash flow growth rate is negative at -84.64%. The operating cash flow to net income ratio is slightly above 1, indicating operating losses are closely aligned with net income losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	235.00K	353.00K	10.39M	0.00	10.46M
Gross Profit	-383.00K	-1.30M	-2.39M	8.69M	-1.30M	-6.84M
EBITDA	-65.90M	-66.37M	-52.18M	-44.71M	-32.47M	-14.64M
Net Income	-63.41M	-64.02M	-50.39M	-45.34M	-33.77M	-16.22M
Balance Sheet
Total Assets	97.25M	96.83M	120.65M	95.79M	115.54M	38.73M
Cash, Cash Equivalents and Short-Term Investments	76.35M	72.13M	98.17M	66.15M	107.91M	31.69M
Total Debt	12.99M	13.28M	15.10M	11.53M	1.38M	2.24M
Total Liabilities	22.38M	27.00M	30.18M	24.50M	6.41M	7.24M
Stockholders Equity	75.05M	70.02M	90.66M	71.46M	109.30M	31.65M
Cash Flow
Free Cash Flow	-62.21M	-69.18M	-37.44M	-43.53M	-33.27M	-15.50M
Operating Cash Flow	-62.16M	-69.12M	-33.22M	-41.89M	-33.08M	-15.30M
Investing Cash Flow	14.17M	17.23M	-20.13M	47.24M	-91.57M	6.90M
Financing Cash Flow	50.76M	39.86M	66.23M	5.45M	110.03M	16.14M

aTyr Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATYR, the sentiment is Positive. The current price of 5.31 is above the 20-day moving average (MA) of 5.05, above the 50-day MA of 4.02, and above the 200-day MA of 3.34, indicating a bullish trend. The MACD of 0.37 indicates Positive momentum. The RSI at 62.18 is Neutral, neither overbought nor oversold. The STOCH value of 23.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATYR.

aTyr Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATAI	59 Neutral	$497.87M	―	-62.43%	―	-0.90%	-89.51%
ARCT	57 Neutral	$363.69M	―	-27.40%	―	15.40%	35.42%
GLUE	52 Neutral	$285.41M	70.54	2.88%	―	―	61.09%
ATYR	51 Neutral	$443.24M	―	-79.51%	―	-100.00%	10.73%
Sector *	48 Neutral	AU$2.46B	3.71	-64.25%	2.95%	35.15%	13.63%
OLMA	46 Neutral	$286.69M	―	-41.59%	―	―	0.42%
AURA	43 Neutral	$381.33M	―	-56.24%	―	―	9.22%

aTyr Pharma Corporate Events

aTyr Pharma Stockholders Approve Key Proposals at Annual Meeting

At the recent Annual Meeting, aTyr Pharma‘s stockholders approved several key proposals, including the election of two Class I directors, the ratification of Ernst & Young LLP as the independent public accounting firm for the fiscal year ending December 31, 2025, and the approval of amendments to the 2015 Stock Plan. These decisions, supported by a significant number of votes, reflect the company’s strategic direction and governance priorities, potentially impacting its operational and financial strategies moving forward.